Power Integrations Rolls Out Reference Design Kit for Solar Race Cars Featuring High-Efficiency Gallium-Nitride IC
22.8.2025 00:00:00 CEST | Business Wire | Press Release
Power Integrations is rolling out a new reference design kit tailored specifically for solar-powered race cars as 37 student teams prepare to race across the Outback in the Bridgestone World Solar Challenge starting August 24.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250821250611/en/
RDK-85SLR includes everything needed to create a 46-watt power supply. Solar race car teams can get the kit free by registering online.
The kit, RDK-85SLR, features the PI™ InnoSwitch™3-AQ IC , which incorporates PI’s PowiGaN™ gallium-nitride switch technology. The kit is inspired by a design created by PI’s PowerPros℠ online support engineers in collaboration with the ETH Zurich aCentauri team, whose #85 ‘Silvretta’ challenger-class car is using the design to maximize efficiency in its auxiliary power supply.
“Thousands of engineering students participate in solar car challenges around the world each year, and these innovators will help bring about a more sustainable future,” said Andy Smith, director of technical outreach and training for Power Integrations. “We are providing this reference kit to help young engineers take advantage of the latest, most energy-efficient technologies, such as PowiGaN, in their designs.”
The design kit includes everything needed to create a 46-watt power supply that delivers up to 80 watts for short periods—making it ideal for use as an auxiliary power supply in a solar race car. It employs the company’s InnoSwitch3-AQ flyback power supply IC with a highly efficient PowiGaN switch and eliminates the need for a heatsink, enabling more compact, lightweight, and cost-effective designs. Contents of the kit include a sample power supply, four InnoSwitch3-AQ ICs, and an unpopulated PCB. It is backed by a report containing power supply and magnetics transformer build instructions, schematics, a PCB layout guide, a parts list and comprehensive performance data. Live tech support is available from Power Integrations’ PowerPros team.
“We proved PowiGaN’s reliability, performance and efficiency in the Bridgestone World Solar Challenge in 2023,” stated Aaron Griesser, lead electrical engineer from the 2023 aCentauri team. “We achieved 95 percent efficiency across both light and full loads with a broad output range of 5 to 60 W. Additionally, the scrutineering judges were astounded to see an auxiliary power supply without a heatsink.”
Power Integrations is a proud sponsor of the aCentauri team and will be reporting on the race from Mr. Green’s Blog and PI’s social media channels using hashtag #PowiGaNVan.
Availability & Resources
Reference design kit RDK-85SLR is priced at $50. Solar race car teams can get the kit free by registering online.
About Power Integrations
Power Integrations, Inc., is a leading innovator in semiconductor technologies for high-voltage power conversion. The company’s products are key building blocks in the clean-power ecosystem, enabling the generation of renewable energy as well as the efficient transmission and consumption of power in applications ranging from milliwatts to megawatts. For more information, please visit www.power.com.
Power Integrations, the Power Integrations logo, PI, PowiGaN, PowerPros and InnoSwitch3-AQ are trademarks, service marks or registered trademarks of Power Integrations, Inc. All other trademarks are the property of their respective owner.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250821250611/en/
Contacts
Media Contact
Linda Williams
Power Integrations
(408)-414-9837
linda.williams@power.com -
linda.williams@power.com?subject=PR-08-22-2025-GLOBAL-Solar-Race-Car-RDK-85SLP
Press Agency Contact
Nick Foot
BWW Communications
+44-1491-636 393
nick.foot@bwwcomms.com -
nick.foot@bwwcomms.com?subject=PR-08-22-2025-GLOBAL-Solar-Race-Car-RDK-85SLP
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom